P/B
4,4
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.
$1.7B
Market Cap • 10/13/2026
2019
(7 years)
Founded
2024
(2 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
17,2
P/EBITDA
—
P/OCF
16
P/FCF
16,2
P/E
—
BVPS
8,3
EPS
—
Market Cap
Market Cap
1,7B
EV
1,3B
EV/Revenue
13,7
EV/EBITDA
-32,2
EV/EBIT
-31
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-1,1%
Total Yield
-1,1%
Payout
0%
Retained Earnings
-188,9M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
122,2%
Capex/Revenue
0,9%
Capex/D&A
55,2%
Capex/OCF
0,9%
SBC/OCF
15,4%
% PPE
4,3%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
8,3
Debt/Equity
0%
Current Ratio
5
Quick Ratio
4,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!